He replaces acting CEO, Franz Obermayr, Ph.D., who reassumes his position as EVP clinical development of EyeGate.
Dr. Strem was a co-founder and former CEO of Okogen, as well as a co-founder and managing director of Bayon Therapeutics. He brings strategic expertise, scientific acumen and drug development experience in ophthalmology, otology and regenerative medicine to EyeGate.
In addition, EyeGate entered into a non-binding letter of intent to acquire closely-held Bayon Therapeutics, an ophthalmic specialty pharmaceutical company focused on using light sensitive “photoswitch” small molecules, specifically designed to restore vision in patients with inherited and age-related degenerative retinal diseases.
“We have the greatest confidence in Brian and the executive team’s ability to marshal the necessary resources to maximize the value of our platform, explore additional pipeline expansion opportunities and successfully lead EyeGate through this next phase of continued growth,” executive chairman, Stephen From, said in a statement.